Lv1
10 积分 2023-03-11 加入
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?
2天前
已完结
Integrin-based therapy in IBD
2天前
已完结
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
3天前
已完结
Emerging therapeutic opportunities for integrin inhibitors
6天前
已完结
Antibody Responses in Mice to Particles Formed from Adsorption of a Murine Monoclonal Antibody onto Glass Microparticles
9天前
已完结
Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series
11天前
已完结
Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn’s Disease
12天前
已完结
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
12天前
已完结
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
21天前
已完结
Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation
24天前
已完结
皖公网安备34019202002308
